Robert Kilkuskie
Direktor/Vorstandsmitglied bei Michigan High Throughput Screening Center
Aktive Positionen von Robert Kilkuskie
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Michigan High Throughput Screening Center
Michigan High Throughput Screening Center Miscellaneous Commercial ServicesCommercial Services Michigan High Throughput Screening Center develops screening technologies for drug discovery. It offers services to academic institutions, biotechnology & pharmaceutical companies, and government laboratories. The firm is a not-for-profit contract research organization. Its scientists has extensive experience in drug discovery research and have experience in developing, validating and implementing high throughput screening assays for a broad range of drug targets in central nervous system disease, inflammation, infectious diseases, and oncology. It also has an extremely diverse library containing 100,000 drug able compounds and requires no licensing fees or royalties. | Direktor/Vorstandsmitglied | - | - |
National Institute of Health Policy | Corporate Officer/Principal | 30.04.2010 | - |
Karriereverlauf von Robert Kilkuskie
Statistik
International
Vereinigte Staaten | 3 |
Operativ
Director/Board Member | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Michigan High Throughput Screening Center
Michigan High Throughput Screening Center Miscellaneous Commercial ServicesCommercial Services Michigan High Throughput Screening Center develops screening technologies for drug discovery. It offers services to academic institutions, biotechnology & pharmaceutical companies, and government laboratories. The firm is a not-for-profit contract research organization. Its scientists has extensive experience in drug discovery research and have experience in developing, validating and implementing high throughput screening assays for a broad range of drug targets in central nervous system disease, inflammation, infectious diseases, and oncology. It also has an extremely diverse library containing 100,000 drug able compounds and requires no licensing fees or royalties. | Commercial Services |
National Institute of Health Policy |
- Börse
- Insiders
- Robert Kilkuskie
- Erfahrung